 |
Indication & Dosage |
| |
| |
| Oral |
| HYPERTENSION |
| Adult:
(Captopril 25mg, hydrochlorothiazide 25mg) 1 tab 2 or 3 times a day |
| |
| Oral |
| CHF |
| Adult:
(Captopril 25 mg, hydrochlorothiazide 25 mg) 1 tab 2 or 3 times a day. |
|
| |
|
| Administration |
Should be taken on an empty stomach (i.e. At least one hour before food or four hours after food). (Take on an empty stomach 1 hr before meals.) |
| |
|
| Precautions |
Neonates and children, elderly patients, renal disease, liver disease, diabetes mellitus, gout, hyperlipidaemia, ECG evidence of LVH, ventricular ectopics pregnancy and lactation. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Skin rashes, dysgeusia, cough, hypochloraemic alkalosis, rarely haemolytic anaemia, thrombocytopenia, jaundice, pancreatitis, noncardiogenic pulmonary oedema, hypomagnesaemia leading to fatigue, weakness and paralysis. Hyperuricaemia, impotence in diabetics, significant reduction in tear production and glucose tolerance and increase in plasma Ca concentrations. |
| |
|
| Adverse Drug Reactions |
Hyperkalaemia in patients having renal impairment, rarely idiosyncratic hypersensitivity reactions like Stevens-Johnson syndrome, SLE and acute pancreatitis. Severe hyponatraemia. |
| |
|
| Interactions |
Increase in bone marrow depression on concomitant therapy with immunosuppressants. Analgesic and resp depression effects of morphine potentiated. Potentiation of nephrotoxicity caused by aminoglycosides, precipitation of digitalis toxicity and lithium toxicity by thiazide diuretics. Hypotensive action of captopril blunted by NSAIDs. Impairment in glycaemic control by thiazides. Decreased renal excretion of captopril by probenecid. Hypotensive effect of captopril may be increased by other hypotensives. Symptomatic hyponatremia and impaired renal function may result with concomitant use of carbamazepine and allopurinol. Thiazide absorption is increased and decreased by anticholinergics and cholestyramine respectively. Food reduces absorption of captopril. |
| |
|
|
|
